KPV

KPV is like a prototype that passes every lab test and works perfectly in mice, but has never been tried in a real human factory. The design looks sound on paper. Whether it actually works safely at human scale remains unknown.

KPV is the C-terminal tripeptide of alpha-MSH. Its anti-inflammatory action, as characterised preclinically, appears largely independent of melanocortin receptors. It crosses intestinal epithelial and immune cells via the peptide transporter PepT1, which is upregulated in inflamed colonic mucosa. Once inside cells, KPV inhibits NF-kB activation by preserving IkBalpha and blocking p65 nuclear translocation, and dampens MAP kinase signalling. This reduces production of pro-inflammatory cytokines such as TNF-alpha and IL-6. Alpha-MSH-derived peptides including KPV have also been reported to show direct antimicrobial activity against Candida albicans and Staphylococcus aureus in vitro, though these findings are contested. Routes studied preclinically include oral, topical and parenteral.

Research contexts. Not proven uses, and not recommendations.

None. Despite widespread marketing claims for gut health, eczema and recovery, there are no completed or registered human clinical trials of KPV in any indication. The entire efficacy case rests on in-vitro cell work and animal studies. Human pharmacokinetics, dosing, absorption, immunogenicity, drug interactions and long-term safety are completely uncharacterised. Any clinical claim is unsupported by human data.

• !No human clinical trial data; efficacy and safety in people are unknown.
• !Sold in the UK as an unlicensed 'research chemical' / 'not for human consumption', with no regulatory oversight of purity, sterility, dose accuracy or contaminants.
• !Marketing routinely claims human benefits based solely on laboratory findings.
• !Some preclinical claims (e.g. antimicrobial activity) have not been consistently reproduced.
• !Long-term effects and immunogenicity in humans are uncharacterised.
• !Injectable grey-market use carries sterility, dosing and contamination risks inherent in unlicensed self-administered products.
• !A strong preclinical mechanism does not guarantee clinical benefit. Many anti-inflammatory peptides have failed to translate to humans.

Not a licensed medicine in the UK. KPV has no MHRA marketing authorisation and is not an approved prescription drug. It also has no approval from the FDA or EMA. It is sold almost exclusively as an unlicensed research chemical labelled 'not for human consumption'. Selling or supplying it for human medicinal use without authorisation would breach the Human Medicines Regulations 2012. There is no recognised UK medical indication.

1. 01
   PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation — Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, Yan Y, Sitaraman S, Merlin D, Gastroenterology (2008)

   Landmark preclinical paper: nanomolar KPV inhibits NF-kB and MAPK signalling via hPepT1 and reduces DSS- and TNBS-induced colitis in mice.

2. 02
   Antimicrobial effects of alpha-MSH peptides — Cutuli M, Cristiani S, Lipton JM, Catania A, Journal of Leukocyte Biology (2000)

   Reports direct antimicrobial activity of alpha-MSH and its C-terminal fragment (KPV) against S. aureus and C. albicans in vitro.

3. 03
   Alpha-Melanocyte Stimulating Hormone: An Emerging Anti-Inflammatory Antimicrobial Peptide — Singh M, Mukhopadhyay K, BioMed Research International (2014)

   Review covering alpha-MSH and fragment (including KPV) anti-inflammatory and antimicrobial biology.

4. 04
   Critical Role of PepT1 in Promoting Colitis-Associated Cancer and Therapeutic Benefits of the Anti-inflammatory PepT1-Mediated Tripeptide KPV in a Murine Model — Wu D, Wang X, et al., Cellular and Molecular Gastroenterology and Hepatology (2016)

   Further murine evidence that PepT1-transported KPV is anti-inflammatory in colitis-associated cancer models. Still strictly preclinical.